Nektar Therapeutics Files 2024 10-K
Ticker: NKTR · Form: 10-K · Filed: Mar 14, 2025 · CIK: 906709
Sentiment: neutral
Topics: 10-K, pharmaceuticals, restructuring, financials
TL;DR
Nektar's 2024 10-K is in, detailing restructuring and asset sales. Check financials.
AI Summary
Nektar Therapeutics filed its 10-K for the fiscal year ending December 31, 2024, reporting on its operations and financial condition. The company, headquartered in San Francisco, CA, is involved in the pharmaceutical preparations industry. Key events and disclosures within the filing relate to restructuring plans, asset impairments, and fair value measurements.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Nektar Therapeutics' financial performance and strategic activities for the past fiscal year, including details on restructuring and asset management.
Risk Assessment
Risk Level: medium — The filing contains information on restructuring costs, asset impairments, and fair value disclosures, which can indicate financial challenges or strategic shifts.
Key Numbers
- 2834 — SIC Code (Identifies Nektar Therapeutics' industry as Pharmaceutical Preparations.)
- 943134940 — IRS Number (Nektar Therapeutics' IRS identification number.)
Key Players & Entities
- Nektar Therapeutics (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- San Francisco, CA (location) — Company headquarters
- Ampersand Capital Partners (company) — Involved in an asset acquisition
- 2022 Restructuring Plan (event) — Mentioned in relation to employee severance and facility matters
FAQ
What were the significant restructuring costs or asset impairments reported in the 2024 10-K?
The filing references 'RestructuringCostsAndAssetImpairmentCharges' and mentions a 'TwoThousandTwentyTwoRestructuringPlan' in relation to employee severance and facility matters, suggesting these were significant areas of focus.
Did Nektar Therapeutics engage in any asset acquisitions or dispositions during the 2024 fiscal year?
Yes, the filing mentions 'AssetAcquisitionByAmpersandCapitalPartnersMember' and 'DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember' for the period of 2024-01-01 to 2024-12-31.
What is the company's primary business as indicated by its Standard Industrial Classification (SIC) code?
Nektar Therapeutics' SIC code is 2834, which corresponds to 'Pharmaceutical Preparations'.
What is the company's physical address and phone number?
The business address is 455 Mission Bay Boulevard South, San Francisco, CA 94158, and the business phone number is 4154825300.
What former company names has Nektar Therapeutics used?
Nektar Therapeutics was formerly known as INHALE THERAPEUTIC SYSTEMS INC, with a name change on 19980723, and prior to that, INHALE THERAPEUTIC SYSTEMS, with a name change on 19940303.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 14, 2025 regarding NEKTAR THERAPEUTICS (NKTR).